Safety and Effectiveness of Arcuate Incisions Performed With the iFS Femtosecond Laser System
- Conditions
- Corneal Astigmatism
- Registration Number
- NCT01348854
- Lead Sponsor
- Abbott Medical Optics
- Brief Summary
To determine if arcuate incisions performed with the iFS femtosecond laser are safe and effective in reducing corneal astigmatism.
- Detailed Description
Surgeons will perform arcuate incisions in the cornea in arc segment patterns using the iFS femtosecond laser to treat subjects with corneal astigmatism.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
-
Male or female, of any race, and at least 21 years of age at the time of pre-op exam
-
Corneal astigmatism, as determined by topographic keratometry, of 0.75 D to 4.00 diopters (D)
-
Best Spectacle Corrected Distance Visual Acuity (BSCVA)
-
Group 1:
- Natural astigmatism, no cataract - BSCVA of 20/25 or better
- Pre cataract or phakic IOL surgery - no BSCVA criteria
-
Group 2:
- Post IOL surgery- BSCVA of 20/25 or better
-
-
Uncorrected Visual Acuity (UCVA) of 20/40 or worse
-
Demonstration of agreement: Corneal astigmatism (as determined by topographic keratometry) must be in agreement with refractive astigmatism (as determined by manifest refractions) within </= 0.75 D in magnitude and 15 degrees axis when cylinder </= 1.5 D or 10 degrees axis when cylinder > 1.5 D.
-
Preoperative central pachymetry of >/=480 um
-
Keratometry between 38.0 D (flat) to 48.0 D (steep)
-
Corneal power (diopters) difference at the 3mm point from topographic center shall be </= 1D at the steepest meridian
-
Intraocular pressure of 12 to 21 mm Hg with no glaucomatous retinal/optic nerve changes
-
Subjects who have worn a contact lens within the past 30 days must remove the soft lens at least 2 weeks prior and a rigid or toric lens at least 3 weeks prior to baseline measurements
-
Willing and capable of returning for follow-up examinations for the duration of the study
- Angle kappa of greater than 0.5 mm, absolute value
- Prior implantation of toric or multifocal intraocular lens
- Women who are pregnant, breast-feeding, or intend to become pregnant over the course of the study
- Concurrent use of topical or systemic medications that may impair corneal wound healing
- History of any ocular or medical conditions that could affect corneal wound healing
- History of active or recurrent ophthalmic disease, including corneal dystrophy or other non-refractive abnormality such as exposure keratitis or clinically significant dry eye
- Abnormal topography, including evidence of keratoconus or pellucid marginal degeneration in either eye
- Evidence of clinically significant corneal opacity/scar in the operative eye(s) within an 8 mm diameter zone of the visual axis
- Known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course
- Participation in any other conflicting clinical study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Reduction of Astigmatism 6 months Reduction of astigmatism as determined by manifest refractive cylinder
- Secondary Outcome Measures
Name Time Method Percent of Eyes With Loss of ≥ 2 Lines of Best Spectacle Corrected Visual Acuity (BSCVA) 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (4)
Paracelsus Medizinische Privat-Universitat, PMU
🇦🇹Salzburg, Austria
CHU Morvan
🇫🇷Brest, France
Bochum-Langendreer
🇩🇪Bochum, Germany
Potsdamer Augenklinik im
🇩🇪Potsdam, Germany
Paracelsus Medizinische Privat-Universitat, PMU🇦🇹Salzburg, Austria